Home

Deerfield Mgmt III, L.P.

CIK 1610540 · last filed 2026-03-02

Deerfield Mgmt III, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 9 companies since 2015. The most recent filing shows the insider bought $250.0M of LRMR on Mar 2, 2026. Across all open-market trades the lifetime net is +$146.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $54.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$54.33M

Companies

9

Total Filings

9

Lifetime Open-Market Net

$146.73M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LRMR Director 6,207,982 $3.83 $23.78M $250.00M 1 2026-03-02
SPRY 10%+ Owner 4,887,254 $5.67 $27.71M -$81.98M 1 2025-07-01
GUTS 10%+ Owner 834,254 $0.72 $602.8K $0 1 2024-02-08
Oncorus, Inc. (ONCR) Delisted 10%+ Owner 1,400,972 $0.12 $168.9K -$42.7K 1 2022-12-15
Q32 Bio Inc. (FIXX) Delisted 10%+ Owner 7,150 $16.82 $120.3K -$61.46M 1 2019-12-27
Shockwave Medical, Inc. (SWAV) Delisted 10%+ Owner 132,740 $334.75 $44.43M $3.06M 1 2019-03-11
EDIT 10%+ Owner 854,700 $2.62 $2.24M $9.60M 1 2016-02-08
ALIMERA SCIENCES INC (ALIM) Delisted 10%+ Owner 13,844 $5.54 $76.7K $6.56M 1 2015-12-08
Neos Therapeutics, Inc. (NEOS) Delisted 10%+ Owner 429,166 $1.15 $493.5K $21.00M 1 2015-07-28

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-02 LRMR Buy (P) +50,000,000 $250.00M EDGAR
2025-07-01 SPRY Sell (S) −4,440,894 -$81.98M EDGAR
2024-02-08 GUTS Conv (C) +3,337,016 $0 EDGAR
2022-12-15 Oncorus, Inc. (ONCR) Delisted Sell (S) −110,288 -$42.7K EDGAR
2019-12-27 Q32 Bio Inc. (FIXX) Delisted Sell (S) −2,800,000 -$61.46M EDGAR
2019-03-11 Shockwave Medical, Inc. (SWAV) Delisted Mixed +2,052,876 $3.06M EDGAR
2016-02-08 EDIT Mixed +10,856,400 $9.60M EDGAR
2015-12-08 ALIMERA SCIENCES INC (ALIM) Delisted Buy (P) +2,177,992 $6.56M EDGAR
2015-07-28 Neos Therapeutics, Inc. (NEOS) Delisted Mixed +5,149,992 $36.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.